{"generic":"DTaP, Hepatitis B, Poliomyelitis, H. influenzae type B","drugs":["DTaP, Hepatitis B, Poliomyelitis, H. influenzae type B"],"mono":{"0":{"id":"930440-s-0","title":"Generic Names","mono":"DTaP, Hepatitis B, Poliomyelitis, H. influenzae type B"},"1":{"id":"930440-s-1","title":"Dosing and Indications","sub":{"1":{"id":"930440-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Infanrix hexa (diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b) vaccine has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li>safety and efficacy in children older than 36 months not established<\/li><li>if a dose of hepatitis B vaccine is given at birth, then Infanrix hexa may be used in place of supplementary doses of hepatitis B from 6 weeks of age; if a second dose of hepatitis B is required before 6 weeks of age, then use monovalent hepatitis B vaccine<\/li><li><b>Haemophilus influenzae type b vaccination - Hepatitis B vaccination - Poliomyelitis vaccination - Vaccination for diphtheria, pertussis, and tetanus:<\/b> primary series, 0.5 mL IM for 3 doses separated by at least 1-month intervals (eg, 2, 3, 4 months; 3, 4, 5 months; 2, 4, 6 months) or 2 doses (eg, 3, 5 months); premedicate with antipyretic (European Medicines Agency-approved dosing)<\/li><li><b>Haemophilus influenzae type b vaccination - Hepatitis B vaccination - Poliomyelitis vaccination - Vaccination for diphtheria, pertussis, and tetanus:<\/b> primary series, Expanded Program on Immunization schedule (6, 10, 14 weeks) 0.5 mL IM for 3 doses only if hepatitis B vaccination given at birth; premedicate with antipyretic (European Medicines Agency-approved dosing)<\/li><li><b>Haemophilus influenzae type b vaccination - Hepatitis B vaccination - Poliomyelitis vaccination - Vaccination for diphtheria, pertussis, and tetanus:<\/b> booster after 2 doses, 0.5 mL IM at least 6 months after last priming dose, preferably between 11 and 13 months of age  (European Medicines Agency-approved dosing)<\/li><li><b>Haemophilus influenzae type b vaccination - Hepatitis B vaccination - Poliomyelitis vaccination - Vaccination for diphtheria, pertussis, and tetanus:<\/b> booster after 3 doses, 0.5 mL IM at least 6 months after last priming dose, preferably before 18 months of age  (European Medicines Agency-approved dosing)<\/li><\/ul>"},"3":{"id":"930440-s-1-7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Haemophilus influenzae type b vaccination - Hepatitis B vaccination - Poliomyelitis vaccination - Vaccination for diphtheria, pertussis, and tetanus<br\/>"}}},"3":{"id":"930440-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930440-s-3-9","title":"Contraindications","mono":"<ul><li>encephalopathy of unknown etiology within 7 days of pertussis-containing vaccination; discontinue pertussis vaccination and proceed only with diphtheria-tetanus, hepatitis B, polio, and Hemophilus influenza vaccination<\/li><li>febrile illness, acute and severe; postpone vaccination<\/li><li>hypersensitivity to diphtheria, tetanus, or Hemophilus influenza type B toxoids, pertussis, or hepatitis B antigens, or poliovirus, or to any component of the vaccine, including neomycin and polymyxin, or hypersensitivity after previous administration of any component of the vaccine<\/li><\/ul>"},{"id":"930440-s-3-10","title":"Precautions","mono":"<ul><li>anaphylaxis may occur<\/li><li>bleeding disorder; increased risk of bleeding after IM administration<\/li><li>convulsions, history of febrile; increased risk for occurrence within 2 to 3 days of vaccination<\/li><li>immunosuppression, including HIV infection or use of immunosuppressive therapy; immunologic response may not be adequate<\/li><li>neurologic disorder, severe, new-onset or progression; consider benefits and risks of administering or deferring vaccination<\/li><li>prematurity; immunologic response and clinical protection may not be adequate<\/li><li>subsequent doses of pertussis-containing vaccines should be reconsidered if a vaccinee develops any of the following events in temporal relation to administration: unexplained temperature of 40 degrees C or higher within 48 hours, collapse or shock-like state (hypotonic-hyporesponsive) within 48 hours, persistent crying lasting 3 hours or more within 48 hours, convulsions with or without fever within 3 days; readminister pertussis-containing vaccine only if potential benefit outweighs risks (eg, high incidence of pertussis)<\/li><li>thrombocytopenia; increased risk of bleeding after IM administration<\/li><li>very premature infants (born 28 weeks of gestation or less), consider risk of apnea and need for respiratory monitoring for 48 to 72 hours after primary immunization series, especially in infants with a history of respiratory immaturity; do not withhold or delay vaccination<\/li><\/ul>"},{"id":"930440-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Diphtheria Toxoid, Adsorbed: C (FDA)<\/li><li>Diphtheria Toxoid, Adsorbed: A (AUS)<\/li><li>Haemophilus B Vaccine: C (FDA)<\/li><li>Haemophilus B Vaccine: B2 (AUS)<\/li><li>Hepatitis B Vaccine Recombinant: C (FDA)<\/li><li>Hepatitis B Vaccine Recombinant: B2 (AUS)<\/li><li>Pertussis Vaccine: Fetal risk cannot be ruled out. (TH)<\/li><li>Poliovirus Vaccine, Inactivated: C (FDA)<\/li><li>Poliovirus Vaccine, Inactivated: B2 (AUS)<\/li><li>Tetanus Toxoid: C (FDA)<\/li><li>Tetanus Toxoid: A (AUS)<\/li><\/ul>"},{"id":"930440-s-3-12","title":"Breast Feeding","mono":"<ul><li>Diphtheria Toxoid, Adsorbed: WHO: Compatible with breastfeeding.<\/li><li>Diphtheria Toxoid, Adsorbed: Micromedex: Infant risk is minimal.<\/li><li>Haemophilus B Vaccine: Micromedex: Infant risk is minimal.<\/li><li>Hepatitis B Vaccine Recombinant: WHO: Compatible with breastfeeding.<\/li><li>Hepatitis B Vaccine Recombinant: Micromedex: Infant risk is minimal.<\/li><li>Pertussis Vaccine: WHO: Compatible with breastfeeding.<\/li><li>Pertussis Vaccine: Micromedex: Infant risk is minimal.<\/li><li>Poliovirus Vaccine, Inactivated: WHO: Compatible with breastfeeding.<\/li><li>Poliovirus Vaccine, Inactivated: Micromedex: Infant risk is minimal.<\/li><li>Tetanus Toxoid: Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},"4":{"id":"930440-s-4","title":"Drug Interactions","sub":{"1":{"id":"930440-s-4-14","title":"Major","mono":"<ul>Cyclosporine (theoretical)<\/ul>"},"2":{"id":"930440-s-4-15","title":"Moderate","mono":"<ul><li>Chloramphenicol (probable)<\/li><li>Meningococcal Vaccine, Tetanus Toxoid Conjugate Quadrivalent (established)<\/li><\/ul>"}}},"5":{"id":"930440-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (10% or greater), Injection site pain (10% or greater), Swelling at injection site (10% or greater)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (1% to less than 10%), Loss of appetite (10% or greater), Vomiting (1% to less than 10%)<\/li><li><b>Psychiatric:<\/b>Crying infant (10% or greater), Feeling nervous (1% to less than 10%), Irritability (10% or greater), Restlessness (10% or greater)<\/li><li><b>Other:<\/b>Fatigue (10% or greater), Fever (10% or greater)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Edema of extremity (0.1% to less than 1%)<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Collapse, Seizure (less than 0.01%)<\/li><li><b>Respiratory:<\/b>Apnea, In very premature infants<\/li><li><b>Other:<\/b>Angioedema<\/li><\/ul>"},"6":{"id":"930440-s-6","title":"Drug Name Info","sub":{"1":{"id":"930440-s-6-18","title":"Synonyms","mono":"<ul><li>DTaP, Hepatitis B, Polio and Haemophilus B Vaccine<\/li><li>Diphtheria Toxoid; Tetanus Toxoid; Pertussis Vaccine, Acellular; Hepatitis B Recombinant Vaccine; Poliovirus Vaccine, Inactivated; and Haemophilus B Conjugate Vaccine<\/li><\/ul>"},"2":{"id":"930440-s-6-19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"930440-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"930440-s-9","title":"Administration","mono":"<b>Intramuscular<\/b><br\/><ul><li>administer by deep IM injection only; do not administer intravascularly or intradermally<\/li><li>shake prefilled syringe or vial of diphtheria, tetanus, pertussis, hepatitis, and poliomyelitis vaccine to obtain homogenous turbid white suspension; add contents of syringe or vial to Haemophilus influenzae type b lyophilized powder and shake until powder completely dissolved<\/li><\/ul>"}}}